Condition

Cerebral Amyloid Angiopathy

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common interventions4

Lead sponsors shown3

Clinical trials

4 shown

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)NCT03824197 · 2019-05-07

COMPLETED

Multimodal Biomarkers for Diagnosis and Prognosis in CAANCT03969732 · 2018-09-27

UNKNOWN

Application of Amyloid PET in Cerebral Amyloid AngiopathyNCT03542656 · 2014-09-11

COMPLETED

F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)NCT01382849 · 2011-08-01

WITHDRAWN

Common interventions

1. amyloid PET；2. T807 PETDRUG1 amyloid PETDRUG1 EVOOOTHER1 OOOTHER1

Leading sponsors

National Taiwan University Hospital 2 Auburn University 1 Sunnybrook Health Sciences Centre 1

Trial status mix

COMPLETED2

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.